ArticleCentral European journal of urology2025
Development of a predictive risk score for 1-year intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
Article in Central European journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The study aims to develop and internally validate a novel risk stratification model specifically designed to predict 1-year intravesical recurrence (IVR) following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), integrating readily available clinicopathologic parameters. Material and methods: We retrospectively analyzed 87 patients who underwent RNU for UTUC between 2012 and 2024. Patients were stratified according to IVR status at 12 months postoperatively. Univariate and LASSO logistic regression analyses were conducted to identify independent predictors. A simplified risk score was derived from regression coefficients. Model performance was assessed using area under the ROC curve (AUC), calibration plots, and bootstrap validation. Clinical utility was evaluated with decision curve analysis (DCA). Results: One-year IVR occurred in 34 patients (39.1%). Seven independent predictors were identified: tumor multifocality, ureteral tumor location, history of non-muscle-invasive bladder cancer, chronic kidney disease, preoperative ureteroscopy, intravesical bladder cuff excision, and positive surgical margins. The final model showed excellent discriminative performance (AUC = 0.854) and good calibration. Patients were stratified into low (0-2 points), intermediate (3-5), and high-risk (6-9) groups, with IVR rates of 11.1%, 53.7%, and 80.0%, respectively (p for trend <0.001). DCA demonstrated a favorable net benefit across a wide range of thresholds. Conclusions: We present a novel, internally validated scoring system that integrates routine clinicopathologic parameters to predict early IVR following RNU for UTUC. This tool may support urologists in implementing risk-adapted cystoscopic surveillance protocols and identifying candidates for early intravesical therapy. External validation is warranted prior to clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.